Display options
Cite
Caulier A, Roussel M, Morel P, et al. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021;138(25):2686-2695doi: 10.1182/blood.2021011285.
Caulier, A., Roussel, M., Morel, P., Lombion, N., Branco, B., Galtier, J., Hulin, C., Perrot, A., Richez, V., Michaud, A. V., Touzeau, C., Doyen, C., Mariette, C., Caillot, D., Harel, S., Lenain, P., Ivanoff, S., Fontan, J., Stoppa, A. M., Manier, S., Garderet, L., Leleu, X., Marolleau, J. P., Arnulf, B., Avet-Loiseau, H., & Royer, B. (2021). Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood, 138(25), 2686-2695. https://doi.org/10.1182/blood.2021011285
Caulier, Alexis, et al. "Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience." Blood vol. 138,25 (2021): 2686-2695. doi: https://doi.org/10.1182/blood.2021011285
Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285. PMID: 34479366.
Copy Download .nbib Format: NLM
Share it on

Blood. 2021 Dec 23;138(25):2686-2695. doi: 10.1182/blood.2021011285.

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.

Blood

Alexis Caulier, Murielle Roussel, Pierre Morel, Naelle Lombion, Benoît Branco, Jean Galtier, Cyrille Hulin, Aurore Perrot, Valentine Richez, Anne-Victoire Michaud, Cyrille Touzeau, Chantal Doyen, Clara Mariette, Denis Caillot, Stéphanie Harel, Pascal Lenain, Sarah Ivanoff, Jean Fontan, Anne-Marie Stoppa, Salomon Manier, Laurent Garderet, Xavier Leleu, Jean-Pierre Marolleau, Bertrand Arnulf, Hervé Avet-Loiseau, Bruno Royer

Affiliations

  1. Hematology, CHU Amiens, Amiens, France.
  2. Hematology, CHU Limoges, Limoges, France.
  3. Univ. Lille, ULR 2694-METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France.
  4. Hematology, Centre Hospitalier de Versailles, Le Chesnay, France.
  5. Hematology, CHU Toulouse, Toulouse, France.
  6. Hematology, CHU Bordeaux, Bordeaux, France.
  7. Hematology, CHU Nice, Nice, France.
  8. Hematology, CHU Nantes, Nantes, France.
  9. Hematology, CHU Dinant-Godinne, Namur, Belgium.
  10. Hematology, CHU Grenoble, Grenoble, France.
  11. Hematology, CHU Dijon, Dijon, France.
  12. Hematology, Hôpital Saint-Louis, Paris, France.
  13. Hematology, CHU Rouen, Rouen, France.
  14. Hematology, Hôpital Avicenne, Bobigny, France.
  15. Hematology, CHU Besançon, Besançon, France.
  16. Hematology, Institut Paoli-Calmettes, Marseille, France.
  17. Hematology, CHRU Lille, Lille, France.
  18. Hematology, Hôpital de la Pitié Salpêtrière, Paris, France; and.
  19. Hematology, CHU Poitiers, Poitiers, France.

PMID: 34479366 DOI: 10.1182/blood.2021011285

Abstract

Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age ≤40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high ISS score (HR, 2.14; P = .03), and high-risk cytogenetics (HR, 4.54; P < .0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P < .0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sex-matched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.

© 2021 by The American Society of Hematology.

Publication Types